Regencell Bioscience Holdings Limited (NASDAQ:RGC) Short Interest Update

Regencell Bioscience Holdings Limited (NASDAQ:RGC) was the target of a large decrease in short interest during the month of February. As of February 13th, there was short interest totaling 670,710 shares, a decrease of 13.3% from the January 29th total of 773,634 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average trading volume of 167,394 shares, the short-interest ratio is currently 4.0 days. Based on an average trading volume of 167,394 shares, the short-interest ratio is currently 4.0 days. Currently, 0.1% of the shares of the company are sold short.

Regencell Bioscience Stock Up 6.1%

Shares of NASDAQ RGC opened at $25.45 on Thursday. The firm’s 50 day simple moving average is $29.00 and its 200-day simple moving average is $20.02. Regencell Bioscience has a 12 month low of $0.11 and a 12 month high of $83.60.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RGC. Geode Capital Management LLC grew its position in shares of Regencell Bioscience by 5,637.5% during the 2nd quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock valued at $6,664,000 after acquiring an additional 384,250 shares during the period. Squarepoint Ops LLC purchased a new position in Regencell Bioscience during the second quarter worth approximately $1,701,000. BNP Paribas Financial Markets purchased a new position in Regencell Bioscience during the second quarter worth approximately $768,000. XTX Topco Ltd acquired a new stake in Regencell Bioscience in the third quarter valued at approximately $598,000. Finally, Vident Advisory LLC increased its position in shares of Regencell Bioscience by 65.7% in the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after buying an additional 11,866 shares in the last quarter. Hedge funds and other institutional investors own 0.13% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.